Dendritic cells (DCs) are considered the best antigen presenting cells because they have the ability to acquire different types of pathogens and present their antigens efficiently to T lymphocytes. The Laboratory of Antigen Targeting to Dendritic Cells (ICB-USP) is developing successfully strategies aimed at targeting antigens to DCs in vivo in mice. This strategy is based on the use of a monoclonal antibody (mAb) produced specifically to react with receptors present on the surface of DCs fused to an antigen of interest. One of these receptors is called DEC205 (or CD205). The administration of low doses of chimeric anti-DEC205 mAbs fused proteins derived from different pathogens induces strong T-cell responses and antibody production against the protein used. Dengue is a viral disease that affects millions of people worldwide and various vaccine strategies based on the proteins that make up the viral particles are being studied. Among these proteins, there is the virus envelope (E) protein. The E protein structure can be divided into three domains (I, II and III) which have different functions in the adhesion and invasion of the target cell. Domain III (EDIII) is of particular interest because it appears to contain epitopes against which neutralizing antibodies have been obtained. This research project aims to evaluate in more detail the humoral and cellular immune responses induced after immunization of animals with chimeric anti-DEC205 mAbs fused to the domain III of protein E.
News published in Agência FAPESP Newsletter about the scholarship: